Duc H T, Kinsky R G, Voisin G A
Transplantation. 1982 May;33(5):492-9. doi: 10.1097/00007890-198205000-00006.
Two parameters of enhancing major histocompatibility complex (MHC) antibodies, previously separately studied, namely, Ig class and antigen specificity, have been treated simultaneously. In the experimental model used, Sa 1 tumor cells, indigenous of A/J (H-2a) were grafted on CBA (H-2k) or C57BL/Ks (H-2d) mice. Immune sera specific for the H-2 K/D- or H-2 I coded antigens of the A/J haplotype (anti-Kk, or IAk, IBk, IJk, IEk, or ICd, Sd, Gd, or Dd) and their immunoglobulin fractions (separated on protein A-Sepharose columns) were injected either i.v. or locally as mixture with the challenging Sa 1 cells. Within the limits of the studied system, the following results were obtained: (1) Sa 1 cells do possess Iak antigens at their surface detected by C-dependent cytotoxicity; no ICd, Sd, or Gd products were detected. (2) The bulk of enhancing activity is concentrated in IgG1 anti-K/D antibodies (anti-Dd when Sa 1 was grafted on CBA mice and anti-Kk, on C57BL/Ks). (3) Anti-Iak antibodies have some activity on Sa 1 cells grafted on C57BL/Ks mice. This activity is significant for IgG1 anti-Iak and suggestive for IgG2 of the same specificity. (4) No enhancing activity was detected in the other antibodies: IgG2 anti-Dd, IgG2 anti-Kk, IgG1, or IgG2 anti-ICd, Sd, Gd as well as in fractions containing IgM and IgA antibodies directed against any studied portion of the MHC products. This results are discussed in terms of the mechanisms involved in enhancement.
此前曾分别进行研究的增强主要组织相容性复合体(MHC)抗体的两个参数,即免疫球蛋白类别和抗原特异性,已被同时加以研究。在所用的实验模型中,将源自A/J(H-2a)的Sa 1肿瘤细胞移植到CBA(H-2k)或C57BL/Ks(H-2d)小鼠身上。对A/J单倍型的H-2 K/D或H-2 I编码抗原具有特异性的免疫血清(抗-Kk,或IAk、IBk、IJk、IEk,或ICd、Sd、Gd,或Dd)及其免疫球蛋白组分(在蛋白A-琼脂糖柱上分离),通过静脉注射或与具有挑战性的Sa 1细胞混合后进行局部注射。在所研究的系统范围内,获得了以下结果:(1)通过补体依赖性细胞毒性检测发现,Sa 1细胞表面确实存在Iak抗原;未检测到ICd、Sd或Gd产物。(2)增强活性的大部分集中在IgG1抗-K/D抗体中(当Sa 1移植到CBA小鼠身上时为抗-Dd,移植到C57BL/Ks小鼠身上时为抗-Kk)。(3)抗-Iak抗体对移植到C57BL/Ks小鼠身上的Sa 1细胞具有一定活性。这种活性对于IgG1抗-Iak而言显著,对于相同特异性的IgG2则具有提示作用。(4)在其他抗体中未检测到增强活性:IgG2抗-Dd、IgG2抗-Kk、IgG1或IgG2抗-ICd、Sd、Gd,以及针对MHC产物任何研究部分的含有IgM和IgA抗体的组分。根据增强作用所涉及的机制对这些结果进行了讨论。